4GUPTA EK, ITO MK, Lovastatin and extended - release niacin combination product: the first drug combination for the management of hyperlipidemia. Heart Dis, 2002, 4(2): 124- 137.
5KNOPP RH, ALAGONA P, DAVIDSON M, et al. Equivalent efficacy of a! tine - release form of niacin(Niaspan) given oncea - night versus plain niacin in the management of hyperlipidemia. Metabolism, 1998, 47(9): 1097- 1104.
6GRUNDY SM, CLEEMAN JI, MERZ CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart AssoCiation. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel Ⅲ. Circulation.2004, 110(2):227-239.
7SCHEEN AJ, KULBERTUS H. Clinical study of the momth. Reveral and Proveit: confirmation of the concept "the lower, the better" for cholesterol therapy in patients with coronary heart disease. Rev Med Liege, 2004, 59(3). 167- 173.
8BARTER P. HDL: a recipe for longevity. Atheroseler Suppl, 2004, 5 (2):25 -31.
4DAVIDSON MH.Controversy surrounding the safety of cerivastatin[J].Expert Opin Drug Saf,2002,1 (3):207-212.
5STAFFA JA,CHANG J,GREEN L.Cerivastatin and reports of fatal rhabdomyolysis[J].N Engl J Med,2002,346(7):539-540.
6RATZBRAVO AE,TCHAMBAZ L,KRAHENBUHL-MELCHER A,et al.Prevalence of potentially severe drug-drug interaction in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy[J].Drug Saf,2005,28 (3):203-275.
7BELLOSTA S,PAOLETTI R,CORSINI A,et al.Safety of statins:focus on clinical pharmacokinetics and drug interactions[J].Circulation,2004,109(23 Suppl 1):Ⅲ 50-Ⅲ 57.
8KAJINAMI K,TAKEKOSHI N,SAITO YL.Pitavastatin:efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor[J].Cardiovasc Drug Rev,2003,21 (3):199-215.
9McKENNEY JM.Efficacy and safety of rosuvastatin in treatment of dyslipidemia[J].Am J Health Syst Pharm,2005,62(10):1033-1047.
